BRPI0507076A - quinolinas substituìdas e seu uso como inibidores micobacterianos - Google Patents

quinolinas substituìdas e seu uso como inibidores micobacterianos

Info

Publication number
BRPI0507076A
BRPI0507076A BRPI0507076-7A BRPI0507076A BRPI0507076A BR PI0507076 A BRPI0507076 A BR PI0507076A BR PI0507076 A BRPI0507076 A BR PI0507076A BR PI0507076 A BRPI0507076 A BR PI0507076A
Authority
BR
Brazil
Prior art keywords
alkyl
hydrogen
het
alkyloxy
hydroxy
Prior art date
Application number
BRPI0507076-7A
Other languages
English (en)
Inventor
Jerome Emile George Guillemont
Elisabeth Ther Se Jea Pasquier
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BRPI0507076A publication Critical patent/BRPI0507076A/pt
Publication of BRPI0507076B1 publication Critical patent/BRPI0507076B1/pt
Publication of BRPI0507076B8 publication Critical patent/BRPI0507076B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

QUINOLINAS SUBSTITUìDAS E SEU USO COMO INIBIDORES MICOBACTERIANOS. A presente invenção refere-se a novos derivados de quinolina substituida de acordo com a fórmula geral (la) ou com a fómula geral (lb) bem como a sais, amina quaternárias, formas estereoquimicamente isoméricas, formas tautoméricas e formas de N-óxido desses derivados, onde R¬ 1¬ é hidrogênio, halo, haloalquila, ciano, hidróxi, Ar, Het, alquila, alquilóxi, alquilito, alquiloxialquila, alquiltioalquila, Ar-alquila ou di(Ar)alquila; p é 1, 2, 3 ou 4; R¬ 2¬ é hidrogênio, hidróxi, tio, alquilólxi, alquiloxialquilóxi, alquiltio, mono ou di(alquil)amino ou um radical de fórmula ; R¬ 3¬ é alquila, Ar, Ar-alquila, Het ou Het-alquila; R¬ 4¬ é hidrogênio, alquila ou benzila; R¬ 5¬ é hidrogênio, halo, haloalquila, hidróxi, Ar, alquila, alquilóxi, alquiltio, alquiloxialquila, alquiltioalquila, Ar-alquila ou di(Ar)alquila; ou dois radicais vicinais R¬ 5¬ poderão ser tornados juntos para formar juntamente com o anel fenila ao qual se ligam uma naftila; r é 1,2,3,4 ou 5; R¬ 6¬ é hidrogênio, alquila, Ar ou Het; R¬ 7¬ é hidrogênio ou alquila; R¬ 8¬ é oxo; ou R¬ 7¬ e R¬ 8¬ tomados juntos formam o radical -CH<154>CH-N<154>; Z é CH~ 2~ ou C(<154>O). Os compostos reivindicados são úteis para o tratamento de doenças micobacterianas, particularmente aquelas doenças causadas por micobactérias patogênicas tais como M. tuberculosis, M.bovis, M. avium, M. smegmatis e M. marinum. Também são reivindicados uma composição farmacêutica que contém um composto da presente invenção, o uso dos compostos ou composições reivindicados para a produção de um medicamento para o tratamento de doenças micobacterianas e um processo para preparar os compostos reivindicados.
BRPI0507076A 2004-01-23 2005-01-21 quinolinas substituídas, seu processo de preparação, composição farmacêutica que as compreende e seu uso como inibidores micobacterianos BRPI0507076B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53876804P 2004-01-23 2004-01-23
US60/538,768 2004-01-23
PCT/EP2005/050267 WO2005070924A1 (en) 2004-01-23 2005-01-21 Substituted quinolines and their use as mycobacterial inhibitors

Publications (3)

Publication Number Publication Date
BRPI0507076A true BRPI0507076A (pt) 2007-06-19
BRPI0507076B1 BRPI0507076B1 (pt) 2019-06-25
BRPI0507076B8 BRPI0507076B8 (pt) 2021-05-25

Family

ID=34807224

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0507076A BRPI0507076B8 (pt) 2004-01-23 2005-01-21 quinolinas substituídas, seu processo de preparação, composição farmacêutica que as compreende e seu uso como inibidores micobacterianos

Country Status (20)

Country Link
US (1) US7338949B2 (pt)
EP (1) EP1711492B1 (pt)
JP (1) JP4773975B2 (pt)
KR (1) KR101150172B1 (pt)
CN (1) CN1910177B (pt)
AP (1) AP2188A (pt)
AT (1) ATE392423T1 (pt)
AU (1) AU2005206330B2 (pt)
BR (1) BRPI0507076B8 (pt)
CA (1) CA2553266C (pt)
DE (1) DE602005006101T2 (pt)
EA (1) EA011359B1 (pt)
ES (1) ES2306082T3 (pt)
HK (1) HK1100927A1 (pt)
IL (1) IL177013A0 (pt)
NO (1) NO337705B1 (pt)
NZ (1) NZ547277A (pt)
UA (1) UA85570C2 (pt)
WO (1) WO2005070924A1 (pt)
ZA (1) ZA200606070B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2321A (en) * 2004-01-29 2011-11-16 Janssen Pharmaceutica Nv Quinoline derivatives for use as mycobactrial inhibitor.
CA2528849C (en) * 2005-06-08 2014-01-14 Janssen Pharmaceutica N.V. Quinoline derivatives as antibacterial agents
JO2855B1 (en) 2005-08-03 2015-03-15 شركة جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
JO2837B1 (en) 2005-08-03 2014-09-15 جانسن فارمسيتكا ان في Quinoline derivatives acting as antibacterial agents
US8686002B2 (en) 2005-08-21 2014-04-01 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as binding partners for 5-HT5 receptors
JO2970B1 (en) 2006-12-06 2016-03-15 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JO2684B1 (en) 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان في Quinoline antibacterial derivatives
JO2685B1 (en) 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان في Quinoline antibacterial derivatives
JO3271B1 (ar) 2006-12-06 2018-09-16 Janssen Pharmaceutica Nv مشتقات الكوينولين المضادة للجراثيم
CA2711912A1 (en) * 2008-01-14 2009-07-23 Jyoti Chattopadhyaya Quinoline, naphthalene and conformationally constrained quinoline or naphthalene derivates as anti-mycobacterial agents
AU2013254670B2 (en) * 2012-04-27 2017-03-30 Janssen Pharmaceutica Nv Antibacterial quinoline derivatives
CN104254527B (zh) * 2012-04-27 2017-05-31 詹森药业有限公司 抗菌的喹啉衍生物
ES2911341T3 (es) * 2015-04-29 2022-05-18 The State Of Israel Ministry Of Agriculture & Rural Development Agricultural Res Organization Aro Vo Composiciones antifitopatogénicas

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2270123A1 (en) * 1996-10-28 1998-05-07 Department Of The Army, U.S. Government Compounds, compositions and methods for treating antibiotic-resistant infections
DE69807222T2 (de) * 1997-06-02 2003-04-17 Janssen Pharmaceutica Nv (imidazol-5-yl)methyl-2-quinolinone derivativen als inhibitoren von proliferation der glatten muskelzellen
US6103905A (en) * 1997-06-19 2000-08-15 Sepracor, Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
AU757059B2 (en) * 1997-06-19 2003-01-30 Sepracor, Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
US6838467B2 (en) * 2000-02-24 2005-01-04 Janssen Pharmaceutica N. V. Dosing regimen
MXPA03002907A (es) * 2000-10-02 2003-06-24 Janssen Pharmaceutica Nv Antagonistas receptores metabotropicos de glutamato.
PT2301544E (pt) 2002-07-25 2012-12-10 Janssen Pharmaceutica Nv Novos inibidores de micobactérias

Also Published As

Publication number Publication date
EP1711492B1 (en) 2008-04-16
ZA200606070B (en) 2007-12-27
JP4773975B2 (ja) 2011-09-14
US7338949B2 (en) 2008-03-04
WO2005070924A1 (en) 2005-08-04
WO2005070924A8 (en) 2006-05-11
CN1910177B (zh) 2010-05-05
ATE392423T1 (de) 2008-05-15
NO337705B1 (no) 2016-06-06
AU2005206330A1 (en) 2005-08-04
CN1910177A (zh) 2007-02-07
KR101150172B1 (ko) 2012-05-25
HK1100927A1 (en) 2007-10-05
AP2006003693A0 (en) 2006-08-31
EA200601363A1 (ru) 2006-12-29
CA2553266C (en) 2013-03-12
IL177013A0 (en) 2006-12-10
BRPI0507076B1 (pt) 2019-06-25
DE602005006101D1 (de) 2008-05-29
KR20060127016A (ko) 2006-12-11
JP2007518775A (ja) 2007-07-12
ES2306082T3 (es) 2008-11-01
NZ547277A (en) 2009-08-28
AP2188A (en) 2010-12-14
EP1711492A1 (en) 2006-10-18
AU2005206330B2 (en) 2010-09-16
US20070082895A1 (en) 2007-04-12
DE602005006101T2 (de) 2009-07-02
EA011359B1 (ru) 2009-02-27
CA2553266A1 (en) 2005-08-04
NO20063747L (no) 2006-08-22
BRPI0507076B8 (pt) 2021-05-25
UA85570C2 (uk) 2009-02-10

Similar Documents

Publication Publication Date Title
BRPI0507076A (pt) quinolinas substituìdas e seu uso como inibidores micobacterianos
BRPI0507065B8 (pt) derivados de quinolina, composição que os compreende, seu processo de preparação e seu uso como inibidores micobacterianos
BRPI0312927B8 (pt) &#34;compostos, derivados de quinolina, composição, seu uso como inibidores micobacteriais, bem como processo para preparação dos referidos derivados&#34;.
BRPI0614493B8 (pt) uso de um composto derivado de quinolina, sua combinação, composição farmacêutica, uso da referida combinação, produto, processo para a preparação de um composto e o referido composto
BRPI1011657A2 (pt) derivados aminopropiônicos substituídos como inibidores de neprilisina
BRPI1007622B8 (pt) Composto, composição, método não terapêutico para controlar um nematódeo parasítico e semente revestida
BR112015007182A2 (pt) inibidores de gdf-8
BR112014002675A2 (pt) &#34;quinazolina como inibidores de serina/treonina quinase, seus usos, e composição&#34;
EA200800501A1 (ru) Производные хинолина в качестве антибактериальных средств
SMT201300098B (it) Forme solide di N-(4-(7-azabiciclo[2.2.1]eptan-7-il)-2-(trifluorometil)fenil-4-osso-5-trifluorometil)-1,4-diidrochinolina-3-carbossammide
BRPI0713923B8 (pt) compostos de ciclopentanos de pirimidila hidroxilados e metoxilados, composição farmacêutica compreendendo os referidos compostos, método de preparação de um composto, e uso dos mesmos
UA99617C2 (ru) Производные пирролконденсированного азотсодержащего гетероцикла, их получение и фармацевтическое применение
AR080596A1 (es) Compuestos alquilamido y composiciones farmaceuticas
PE20141167A1 (es) Piridopirazinas sustituidas como inhibidores novedosos de ptk
EA201101566A1 (ru) Производные имидазола и их применение в качестве модуляторов циклинзависимых киназ
WO2010091104A8 (en) Glucosylceramide synthase inhibitors
BRPI0614122A8 (pt) composto derivado de quinolina, composição farmacêutica e uso do referido composto
CY1113535T1 (el) Παραγωγα κινολινης ως αντιβακτηριακοι παραγοντες
PE20190151A1 (es) Derivados de piridinilo, composiciones farmaceuticas y sus usos como inhibidores aoc3
BRPI0612498A8 (pt) derivados de quinolina como agentes antibacterianos
JO3270B1 (ar) مشتقات كوينولين بصفة عوامل مضادة للبكتيريا
BRPI0720251B8 (pt) derivado de quinolina, sua composição farmacêutica, seu uso, combinação e produto compreendendo o mesmo
EA200970537A1 (ru) Антибактериальные производные хинолина

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 25/06/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 25/06/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/01/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 17A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2654 DE 16-11-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.